filmov
tv
Dr. Goy on BR Plus Bortezomib for MCL Treatment
Показать описание
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of bendamustine and rituximab (Rituxan; BR) plus bortezomib (Velcade) as a potential treatment for patients with mantle cell lymphoma (MCL).
0:00:46
0:02:26
0:00:43
0:12:07
0:01:25
0:01:55
0:10:19
1:30:11
0:02:09
0:04:10
0:03:14
0:15:59
0:09:31
0:10:00
1:06:25
0:10:07
0:11:40
0:05:42
0:05:13
0:12:23
0:01:22
0:02:19
0:07:07
0:11:00